Dr Allan on the Importance of BTK Inhibitors and BCL2 Inhibitors in CLL
December 1st 2023John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.
Read More
An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Read More
Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Read More
An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Read More
CLL: Venetoclax in the R/R Setting
Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.
Read More
High-Risk Patients With R/R CLL
A discussion about treatment for high-risk patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Read More
CLL: BTK Inhibitors in the R/R Setting
Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.
Read More
Steven Coutre, MD, provides an overview of the phase 3 GLOW trial, as well as other novel and emerging combinations for the treatment of chronic lymphocytic leukemia (CLL).
Read More
CLL Therapies: Novel Combinations
John Allen, MD, provides an overview of data looking at emerging combinations as initial therapy for chronic lymphocytic leukemia (CLL).
Read More
BCL2 Inhibitors in Previously Untreated CLL
Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.
Read More
ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL
An overview of the h ALPINE trial of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Read More
Mitigating Toxicities Associated With BTK Inhibitors
A continuing discussion about the implications of toxicities with BTK inhibitors.
Read More
Safety and Efficacy of BTK Inhibitors in CLL
A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).
Read More
BTK Inhibitors as Frontline Treatment for CLL
Leukemia experts provide their personal experience using Bruton tyrosine kinase (BTK) inhibitors to treat patients with chronic lymphocytic leukemia (CLL) in the first-line setting.
Read More
Long-Term Experience With Ibrutinib in CLL
Jennifer Woyach, MD, discusses her experience using ibrutinib for chronic lymphocytic leukemia (CLL) in the first-line setting.
Read More
An overview of prognostic models in chronic lymphocytic leukemia (CLL).
Read More
Prognostic Factors in Chronic Lymphocytic Leukemia
A discussion about prognostic factors in patients with newly diagnosed chronic lymphocytic leukemia (CLL).
Read More
Molecular Testing for Newly Diagnosed CLL
Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).
Read More
William Wierda, MD, PhD, leads a panel of experts in a discussion pertaining to the treatment of chronic lymphocytic leukemia (CLL), beginning with the evolving treatment landscape.
Read More
BTK Inhibitors in Relapsed/Refractory CLL
Read More
MURANO Trial Update in R/R CLL
Read More
Utility of MRD Testing in CLL Management
Read More
Venetoclax Combinations, Safety and Efficacy
Read More
Venetoclax and Obinutuzumab in CLL
Read More
Novel Therapies for Relapsed/Refractory CLL
Read More
Relapsed/Refractory CLL: Treatment Selection
Read More